Dual EP2/EP4 PGE2 receptor antagonists increased tumor microenvironment lymphocyte infiltration and significantly reduced disease burden in multiple tumor models, including in the adenomatous polyposis coli (APC)min+/− spontaneous colorectal tumor model, compared with celecoxib. Here, PTGER4 is linked to colorectal neoplasm.